Gapping up
In reaction to strong earnings/guidance:
- PINS +27.2%, MDRX +18.6% (also will divest EPSi to Strata Decision for $365 mln), SEM +15.1%, HURN +13.2%, UAA +13.1%, HTH +12.1%, BRKS +10.2%, DBVT +10.1%, INT +9.5%, NOK +9.4%, WWE +9.2%, AAPL +7.4% (also announces 4-for-1 stock split), TEX +7.4%, ATUS +6.7%, EBS +6.6%, TNDM +6.4%, FLEX +6.4%, FB +6.3%, SLCA +6.1%, CHTR +6.1%, AMZN +6%, CVA +6%, JCI +5.7%, BERY +5.3%, VRTU +5%, LAZ +4.9%, BAND +4.7%, GLPI +4.6%, BLDR +4.6%, DLX +4.4%, DLR +4.2%, MTZ +4.2%, LOCO +4.1%, CACC +4.1%, VFC +4.1%, SPB +4%, CRY +3.6%, ATR +3.5%, ASX +3.5%, PFPT +3.4%, KNSL +3.4%, CHD +3.4%, HIG +3%, MRK +2.9%, TU +2.7%, PSX +2.7%, CXP +2.6%, EA +2.5%, F +2.5%, WY +2.4%, IDXX +2.4%, X +2.3%, TAK +2.2%, EXAS +2.1%, HUBG +2.1%, HRC +2%, BCPC +1.9%, QDEL +1.7%, AIMT +1.6%, CL +1.6%, ABBV +1.6%, BEAT +1.5%, CBOE +1.3%, RARE +1.2%, WETF +1.1%, BGS +1%, CAT +0.9%
Other news:
- TLSA +41.4% (submits patent application for nasal administration of Foralumab for Treatment of COVID-19 Patients)
- AXGT +10.4% (signed a three-year Clinical Supply Agreement with Oxford Biomedica)
- INT +9.5% (to sell Multi Service payment solutions business)
- BNTX +3.5% (BioNTech and Pfizer (PFE) to supply Japan with 120 mln doses of their BNT162 mRNA-based vaccine candidate)
- GSK +1.7% (Sanofi and GSK announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine)
- TTWO +1.5% (announces partnership with the NFL)
- SNY +1% (Sanofi and GSK announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine)
Analyst comments:
- DLR +4.3% (upgraded to Outperform from Mkt Perform at Raymond James)
- COOP +2.3% (upgraded to Overweight from Equal Weight at Barclays)
- HOME +2.2% (upgraded to Buy from Underperform at BofA Securities)
- DNKN +2% (upgraded to Overweight from Neutral at JP Morgan)